Working… Menu

Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01513057
Recruitment Status : Completed
First Posted : January 20, 2012
Last Update Posted : January 20, 2012
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited

Brief Summary:
An open-label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, bioequivalence study of Mycophenolate mofetil 250 mg Capsule of Dr. Reddy's Laboratories limited, comparing with that of Cellcept 250 mg Capsule of Roche Laboratories in healthy, adult, human, male subjects under fed conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Mycophenolate Mofetil Phase 1

Detailed Description:
This was an open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover bioequivalence study in healthy, adult, human, male subjects under fed conditions.64 healthy male adults were enrolled.A washout period of 07 days was maintained between the successive dosing days.One capsule containing mycophenolate mofetil 250 mg was administered orally with 240 mL water in sitting posture, after an overnight fast of at least 10 hours in each period. This activity was followed by a mouth check to assess compliance to dosing. The subjects were not allowed to lie down for the first two hours after dosing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study in Healthy, Adult,Human, Male Subjects Under Fed Conditions.
Study Start Date : January 2009
Actual Primary Completion Date : January 2009
Actual Study Completion Date : February 2009

Arm Intervention/treatment
Experimental: Mycophenolate Mofetil
Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
Drug: Mycophenolate Mofetil
Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited

Active Comparator: Cellcept
Cellcept 250 mg capsules of Roche Laboratories Inc.
Drug: Mycophenolate Mofetil
250 mg capsules of Roche Laboratories Inc.
Other Name: Cellcept

Primary Outcome Measures :
  1. Area Under Curve (AUC) [ Time Frame: pre-dose, 0.167, 0.333,. 0.500, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.75, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, 60.00 and 72.00 hours post dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, adult, human male volunteers between 18 - 55 years of age (both inclusive) living in and around Ahmedabad city of western part of India.
  • Having a Body Mass Index (BMI) between 18.5 - 24.9 (both inclusive), calculated as weight in kg/height in meter2.
  • Have no significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12- lead ECG and X-ray chest recordings.
  • Able to comply with the study procedures, in the opinion of the Principal investigator.
  • Able to give voluntary written informed consent for participation in the study.

Exclusion Criteria:

  • Known hypersensitivity or idiosyncratic reaction to Mycophenolate mofetil or any related drug.
  • Any disease or condition that compromised the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
  • Ingestion of a medicine at any time with in 14 days before dosing in Period-I. In any such case subject selection was at the discretion of the Principal Investigator.
  • Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
  • A recent history of alcoholism (< 2 years) or of moderate (180 mL/day) alcohol use, or consumption of alcohol within 48 hours prior to receiving study medicine.
  • Smokers, who smoked 10 or more than 10 cigarettes/day or inability to abstain from smoking during the study.
  • Consumption of Grapefruits or its products within a period of 48 hours prior to dosing.
  • The presence of clinically significant abnormal laboratory values during screening.
  • Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
  • History of psychiatric disorders.
  • A history of difficulty with donating blood.
  • Donation of blood (1 unit or 350 mL) or receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study medicine. Elimination half-life of the study drug was taken into consideration for inclusion of the subject in the study.

Note: If subject had participated in a study in which blood loss was ≤ 200 mL, subject could be enrolled 60 days after the last sample of previous study.

  • A positive hepatitis screen including hepatitis B surface antigen and HCV antibodies.
  • A positive test result for HIV antibody and/or syphilis.
  • An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medicine and throughout the subjects' participation in the study. In any such case subject selection was at the discretion of the Principal Investigator.

All the enrolled subjects satisfied all the above inclusion and exclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01513057

Layout table for location information
Lambda Therapeutic Research Ltd
Ahmedabad, Gujarat, India, 3 80 061
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Layout table for investigator information
Principal Investigator: Pankaj Kumar Jha, MD Lambda Therapeutic Research Ltd.

Layout table for additonal information
Responsible Party: Dr. Reddy's Laboratories Limited Identifier: NCT01513057     History of Changes
Other Study ID Numbers: 466-08
First Posted: January 20, 2012    Key Record Dates
Last Update Posted: January 20, 2012
Last Verified: January 2012
Keywords provided by Dr. Reddy's Laboratories Limited:
Mycophenolate Mofetil
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action